LQT-1213 is a first-in-class serum glucocorticoid regulated kinase 1 inhibitor. The Food and Drug Administration (FDA) has granted Orphan Drug designation to LQT-1213, a first-in-class serum ...
MONTREAL, /CNW/ - Thryv Therapeutics Inc., a clinical-stage biotechnology company advancing novel serum glucocorticoid inducible kinase 1 (SGK1) inhibitors for inherited cardiac arrhythmias, ...
A machine learning model was more effective at detecting congenital long QT syndrome on resting ECGs than manual measurement of QT intervals by arrhythmia experts, in a new study. Researchers ...
An innovative analysis of shared segments within the genome - an indication of distant "relatedness" - has identified undiagnosed cases of Long QT syndrome, a rare disorder that can lead to abnormal ...
In many low- and middle-income countries, pediatric cardiologists can't help children with congenital heart conditions because of a critical hurdle. They don't have easy access to advanced diagnostic ...
Panera Bread is facing a lawsuit after a college student died after drinking Charged Lemonade. NBC News medical contributor Dr. Kavita Patel explains why caffeine can be extremely dangerous for people ...
MALVERN, Pa., March 25, 2020 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT), a leading remote medical technology company focused on the delivery of health information to improve quality of life ...
MONTREAL, Aug. 25, 2023 /PRNewswire/ - Thryv Therapeutics Inc. today announced positive results of the WAVE 1 Proof of Concept clinical study evaluating LQT-1213 for the reduction of QTcF in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback